Patients taking the drug nearly doubled their survival time, with fewer severe side effects.

Pancreatic cancer remains one of the most fatal cancers. Advances in preclinical and clinical research are breaking down ...

Three new studies from WCLC 2026 show strong results in ROS1-positive NSCLC, EGFR-mutant NSCLC and relapsed small cell lung ...

Cancer science made major progress in the past year but faces an “inflection point” amid funding threats, according to a ...

Pfizer Inc. (NYSE: PFE) will present data from 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the European Society for Medical Oncology (ESMO) Congress, taking ...

The FDA approved the medication more than six months ahead of schedule after trials showed it nearly doubled median survival ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Researchers have unveiled a breakthrough showing that a subset of ...

Today, the American Association for Cancer Research (AACR) released the 16th edition of its annual Cancer Progress Report.

Bloomberg journalists answer your questions about the future of cancer treatment in a Live Q&A on Friday, Sept. 11 at 11 a.m. EDT ...

We preselected all newsletters you had before unsubscribing.

Opinion: Pancreatic cancer has almost no good news. Until now — a new drug nearly doubled survival and earned a standing ovation from doctors, writes Dr. Bryan C. Donohue.

A new study has found that the use of a specific at-home urine test could detect bladder cancer with accuracy. Here are its implications and why this test is a medical breakthrough.